New York, USA, March 07, 2022 (GLOBE NEWSWIRE) -- Frontotemporal Dementia Pipeline Landscape Analysis of 20+ Companies by DelveInsight
With the increasing numbers of promising treatments entering clinical trials, the Frontotemporal Dementia treatment market is expected to grow significantly in the coming years. There are currently 20+ active players working to develop 20+ pipeline therapies for Frontotemporal Dementia treatment.
DelveInsight’s 'Frontotemporal Dementia Pipeline Insight 2022' report provides comprehensive global coverage of available, marketed, and pipeline Frontotemporal Dementia therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Frontotemporal Dementia pipeline domain.
Key Takeaways from the Frontotemporal Dementia (FTD) Pipeline Report
- DelveInsight’s Frontotemporal Dementia Pipeline analysis depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Frontotemporal Dementia treatment.
- Some of the key Frontotemporal Dementia companies developing novel drug candidates to improve the Frontotemporal Dementia treatment landscape include Alector, Prevail Therapeutics, Passage Bio, Inc., Wave Life Sciences Ltd., CAMP4 Therapeutics, Coya Therapeutics, SOLA Biosciences, AcuraStem, Denali Therapeutics, Wave Life Sciences, Neurimmune, Biogen, Asceneuron SA, Libra Therapeutics, Muna Therapeutics, Alkermes, DEEP GENOMICS, Sangamo Therapeutics, LOCANABIO, Arkuda Therapeutics, Yumanity, Autifony Therapeutics, Prothena, Mabylon AG and others.
- Key Frontotemporal Dementia pipeline therapies in various stages of development include AL001, TPN-101, PBFT02, PR006, DNL593 (PTV: PRGN), Research programme: CNS therapeutics, NI308, Research Programme: M1 PAM, AS-203, WVE-004, COYA 102, SOL-257, and others.
- In February 2022, Arkuda Therapeutics, announced the completion of a $64 million Series B financing. The financing was co-led by Cormorant Asset Management and Pivotal bioVenture Partners, with participation from Surveyor Capital (a Citadel company), and Eli Lilly and Company, as well as existing investors Atlas Venture, Pfizer Ventures, funds managed by Tekla Capital Management LLC, and Mission BioCapital.
- In January 2022, The Alzheimer's Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) announced that they have partnered to support Wave Life Sciences' FOCUS-C9 Phase 1b/2a clinical trial investigating WVE-004 as a potential treatment for C9orf72-associated frontotemporal degeneration (C9-FTD), as well as amyotrophic lateral sclerosis (C9-ALS).
- In October 2021, Libra Therapeutics, Inc. announced the appointment of Philip Lambert, Ph.D., as the company’s first CSO. With more than 25 years of drug discovery and development expertise in the areas of neuroscience, metabolic, inflammatory, and orphan diseases and a neuroscientist by training, Dr. Lambert will lead Libra’s development of novel drug candidates focused on restoring the cellular balance lost in neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
- In July 2021, GlaxoSmithKline plc and Alector entered into a strategic global collaboration for the development and commercialization of two clinical-stage, potential first-in-class monoclonal antibodies (AL001 and AL101) designed to elevate progranulin (PGRN) levels.
- In July 2021, Muna Therapeutics announced the successful closing of a USD 73 million (EUR 60 million) Series A financing round. The investor syndicate was co-led by Novo Holdings, Sofinnova Partners, Droia Ventures, and LSP Dementia Fund, with Polaris Partners, Polaris Innovation Fund, Sanofi Ventures, V-Bio Ventures, and VIB joining the round. Muna discovers and develops therapies that slow or stop devastating neurodegenerative diseases including Alzheimer’s, Frontotemporal Dementia, and Parkinson’s.
Request a sample and discover the recent breakthroughs happening FTD pipeline landscape in @ Frontotemporal Dementia Pipeline Outlook
The Frontotemporal Dementia pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Frontotemporal Dementia products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Frontotemporal Dementia pipeline landscape.
Frontotemporal Dementia Overview
Frontotemporal Dementia (FTD) is a term used to describe a set of disorders caused by progressive degeneration of the frontal and temporal lobes of the brain. Behavior, language, and decision-making abilities are all the most common signs and symptoms of Frontotemporal Dementia. FTD is a type of young-onset dementia that strikes people between the ages of 45 and 65. It is the most frequent dementia among people under the age of 60. People in the final Frontotemporal Dementia stages cannot care for themselves. Clinical signs are similar to those of other dementias or psychiatric disorders. It takes an average of 3.6 years from the onset of Frontotemporal Dementia symptoms to a correct diagnosis.
The main Frontotemporal Dementia causes are not still understood but are known as genetic, as around 1 in 8 people who get frontotemporal dementia have a family history of this condition.
Find out more facts about the Frontotemporal Dementia @ Frontotemporal Dementia Posture
A snapshot of the Frontotemporal Dementia Pipeline Drugs mentioned in the report:
| Drugs | Company | Phase | MoA | RoA |
| AL001 | Alector Inc | Phase III | Sortilin inhibitors | Intravenous |
| TPN-101 | Transposon Therapeutics | Phase II | NA | Oral |
| PBFT02 | Passage Bio, Inc. | Phase I/II | Progranulin protein replacements | Intracisternal |
| PR006 | Prevail Therapeutics | Phase II | Progranulin protein replacements | Intracisternal |
| DNL593(PTV:PRGN) | Denali Therapeutics Inc. | IND-enabling | Progranulin protein replacements | Intravenous |
| NI308 | Neurimmune | Preclinical | Immunomodulators | NA |
| Research programme: CNS therapeutics | CAMP4 Therapeutics | Preclinical | NAV1.1 voltage-gated sodium channel expression stimulants | Parenteral |
| Research Programme: M1 PAM | Asceneuron SA | Discovery | NA | NA |
| AS-203 | AcuraStem | Discovery | RNA interference | NA |
Learn more about the novel and emerging pipeline therapies @Frontotemporal Dementia Clinical Trials
Frontotemporal Dementia Therapeutics Assessment
The Frontotemporal Dementia Pipeline report proffers an integral view of the Frontotemporal Dementia emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.
Scope of the Frontotemporal Dementia Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Oral, Intravenous, Inhalation, Subcutaneous
- Therapeutics Assessment By Molecule Type: Gene therapy, Stem cell therapy, Small molecules
- Therapeutics Assessment By Mechanism of Action: Sortilin inhibitors, Progranulin protein replacements, Immunomodulators, RNA interference, NAV1.1 voltage-gated sodium channel expression stimulants
- Key Frontotemporal Dementia Companies: Alector, Prevail Therapeutics, Passage Bio, Inc., Wave Life Sciences Ltd., CAMP4, Therapeutics, Coya Therapeutics, SOLA Biosciences, AcuraStem, Denali Therapeutics, Wave Life Sciences, Neurimmune, Biogen, Asceneuron SA, Libra Therapeutics, Muna Therapeutics, Alkermes, DEEP GENOMICS, Sangamo Therapeutics, LOCANABIO, Arkuda Therapeutics, Yumanity, Autifony Therapeutics, Prothena, Mabylon AG, and others.
- Key Frontotemporal Dementia Pipeline Therapies: AL001, TPN-101, PBFT02, PR006, DNL593(PTV: PRGN), Research programme: CNS therapeutics, NI308, Research Programme: M1 PAM, AS-203, WVE-004, COYA 102, SOL-257, and others.
Dive deep into rich insights for emerging therapies and assessment, visit @ Frontotemporal Dementia Emerging Therapies
Table of Contents
| 1. | Introduction |
| 2. | Executive Summary |
| 3. | Overview |
| 4. | Pipeline Therapeutics |
| 5. | Late Stage Products (Phase III) |
| 5.1. | AL001: Alector Inc. |
| 6. | Mid Stage Products (Phase II) |
| 6.1. | TPN-101: Transposon Therapeutics |
| 7. | Early Stage Products (Phase I/II) |
| 7.1. | PBFT02: Passage Bio |
| 8. | Preclinical Stage Products |
| 8.1. | Research programme: CNS therapeutics: CAMP4 Therapeutics |
| 8.2. | NI308: Neurimmune |
| 9. | Discovery Stage Products |
| 9.1. | Research programme CNS Therapies: Deep Genomics |
| 9.2. | AS-203: AcuraStem |
| 10. | Therapeutic Assessment |
| 11. | Inactive Products |
| 12. | Collaborations Assessment- Licensing / Partnering / Funding |
| 13. | Unmet Needs |
| 14. | Market Drivers and Barriers |
| 15. | Appendix |
| 16. | About DelveInsight |
For further information on the Frontotemporal Dementia current pipeline therapeutics, reach out @ Frontotemporal Dementia Ongoing Clinical Trials
Related Reports
Frontotemporal Dementia Market
Frontotemporal Dementia Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the indication, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers and key Frontotemporal Dementia companies, involved such as TauRx Therapeutics Ltd., Alector, Axon Neuroscience, Passage Bio, Wave Life Sciences, among others.
Dementia with Diabetes Pipeline
Dementia with Diabetes Pipeline Insight, 2022 report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the key Dementia with Diabetes companies involved such as vTv Therapeutics, among others.
Vascular Dementia Pipeline Insight, 2022 report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in the pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the key Vascular Dementia companies involved such as Merz Pharma, Shineway Pharmaceutical, Materia Medica Holding, Acadia Pharmaceuticals, CSPC Ouyi Pharmaceutical, among others.
Lewy Body Dementia Pipeline Insight, 2022 report provides comprehensive insights about pipeline drug profiles, including clinical and non-clinical stage products. It also covers the key Lewy Body Dementia companies involved such as Eisai, Sun Pharma, among others.
AIDS Dementia Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the AIDS Dementia, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key AIDS Dementia companies involved such as BMS, NIAID, Glaxo Wellcome, Beau Nakamoto, among others.
Dementia Associated With Alzheimer's Disease Pipeline
Dementia Associated With Alzheimer's Disease Pipeline Insight, 2022 report provides comprehensive insights about pipeline drug profiles, including clinical and non-clinical stage products. It also covers the key Dementia Associated With Alzheimer's Disease companies involved such as Ortho-McNeil Neurologics, Sunnybrook Health Sciences Centre, Otsuka Pharmaceutical, Solvay Pharmaceuticals, Helse Stavanger HF, among others.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
For more insights, visit Pharma, Healthcare, and Biotech News
